Stock Track | Iovance Biotherapeutics Soars 13.82% Pre-market on Strong Q3 Results and Revenue Growth

Stock Track11-06

Iovance Biotherapeutics, Inc. (IOVA) shares surged 13.82% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results and business achievements. The biotechnology company reported a significant 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million.

The strong performance was driven by robust sales of Amtagvi in the U.S., contributing around $58 million, while global Proleukin revenue added about $10 million to the total. Notably, Iovance's gross margin improved to 43%, which the company attributed to enhanced execution and operational efficiency. The firm also highlighted growing demand for Amtagvi and ongoing integration of community treatment centers, signaling potential for continued growth.

Investors appear to be reacting positively to Iovance's progress in its development programs for solid tumor cancers, as well as the overall strength of its financial results. The pre-market surge suggests that the market is optimistic about the company's future prospects and its ability to capitalize on the growing demand for its products in the biotechnology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197369414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197369414","market":"nz","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Soars 13.82% Pre-market on Strong Q3 Results and Revenue Growth","media":"Stock Track","content":"<p>Iovance Biotherapeutics, Inc. (IOVA) shares surged 13.82% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results and business achievements. The biotechnology company reported a significant 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million.</p>\n\n<p>The strong performance was driven by robust sales of Amtagvi in the U.S., contributing around $58 million, while global Proleukin revenue added about $10 million to the total. Notably, Iovance's gross margin improved to 43%, which the company attributed to enhanced execution and operational efficiency. The firm also highlighted growing demand for Amtagvi and ongoing integration of community treatment centers, signaling potential for continued growth.</p>\n\n<p>Investors appear to be reacting positively to Iovance's progress in its development programs for solid tumor cancers, as well as the overall strength of its financial results. The pre-market surge suggests that the market is optimistic about the company's future prospects and its ability to capitalize on the growing demand for its products in the biotechnology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Soars 13.82% Pre-market on Strong Q3 Results and Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Soars 13.82% Pre-market on Strong Q3 Results and Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics, Inc. (IOVA) shares surged 13.82% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results and business achievements. The biotechnology company reported a significant 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million.</p>\n\n<p>The strong performance was driven by robust sales of Amtagvi in the U.S., contributing around $58 million, while global Proleukin revenue added about $10 million to the total. Notably, Iovance's gross margin improved to 43%, which the company attributed to enhanced execution and operational efficiency. The firm also highlighted growing demand for Amtagvi and ongoing integration of community treatment centers, signaling potential for continued growth.</p>\n\n<p>Investors appear to be reacting positively to Iovance's progress in its development programs for solid tumor cancers, as well as the overall strength of its financial results. The pre-market surge suggests that the market is optimistic about the company's future prospects and its ability to capitalize on the growing demand for its products in the biotechnology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1197369414","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197369414","pubTimestamp":1762434362,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Iovance Biotherapeutics, Inc. (IOVA) shares surged 13.82% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results and business achievements....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"个股追踪|Iovance Biotherapeutics盘前飙升13.82%，得益于强劲的Q3业绩和营收增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Iovance Biotherapeutics, Inc. (IOVA) shares surged 13.82% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results and business achievements. The biotechnology company reported a significant 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million.\nThe strong performance was driven by robust sales of Amtagvi in the U.S., contributing around $58 million, while global Proleukin revenue added about $10 million to the total. Notably, Iovance's gross margin improved to 43%, which the company attributed to enhanced execution and operational efficiency. The firm also highlighted growing demand for Amtagvi and ongoing integration of community treatment centers, signaling potential for continued growth.\nInvestors appear to be reacting positively to Iovance's progress in its development programs for solid tumor cancers, as well as the overall strength of its financial results. The pre-market surge suggests that the market is optimistic about the company's future prospects and its ability to capitalize on the growing demand for its products in the biotechnology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197369414","isCrawlerRequest":true}